Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Biohaven Ltd. on Monday announced that New York-based Oberland Capital has agreed to invest up to $600 million in the New ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...